Online Pharmacy Juniper Faces Advertising Ban Over Exploitative Social Media Campaigns
The Advertising Standards Authority has taken decisive action against online pharmacy Juniper, banning a series of Instagram and Facebook advertisements that were found to promote prescription-only weight-loss medication directly to the public while exploiting the body image insecurities of new mothers. The watchdog's ruling highlights growing concerns about digital marketing practices in the rapidly evolving weight-loss medication sector.
Social Media Campaigns Found to Create Harmful Stereotypes
In one particularly contentious Facebook advertisement from October, a caption accompanying video footage of a woman caring for her baby stated: "I probably needed a hug, but I decided to start a medicated weightloss journey with Juniper instead and I really didn't expect it to bring so much more than progress on the scales. For me it's about my confidence returning, the energy I thought I'd lost and a reminder that showing up for myself was always worth it."
The ASA determined that this messaging, combined with visual content showing the woman walking with a pram and posing for pictures, suggested new mothers should prioritize weight loss after giving birth. The regulator concluded this approach exploited vulnerable women's insecurities and perpetuated harmful gender stereotypes about postpartum body image expectations.
Juniper's Defense and ASA's Rejection
Juniper contested the ASA's interpretation, arguing that their intended message was that mothers could "seek a balance that felt right for them" rather than encouraging weight loss prioritization. However, the ASA maintained its position, stating: "For those reasons, we concluded the ad was irresponsible, as it included a harmful gender stereotype and therefore breached the code."
Black Friday Promotions and Undue Urgency Concerns
The investigation extended to two Instagram advertisements featuring Black Friday promotions in November and December, which included text urging consumers to "Run, don't walk. Save £179 over 6 months... now that's a Black Friday sale." The ASA found these created an undue sense of urgency for individuals considering medicated weight-loss programmes, another violation of advertising standards.
Undisclosed Paid Content in Support Groups
Further violations were discovered in Facebook weight-loss support groups, where posts and comments paid for by Juniper failed to clearly disclose their sponsored nature. One September comment stated: "Juniper's lower wegovy price is a solid deal tbh 25% cheaper than mounjaro. Weight loss results like mounjaro, worth checking while it lasts," while another promoted discount codes for the service.
CheqUp Health, which brought the undisclosed content to the ASA's attention, challenged whether these posts were obviously identifiable as advertising. The watchdog agreed they breached rules by promoting prescription-only medicines to the public without proper disclosure.
Industry Calls for Greater Clarity and Enforcement
CheqUp founder Toby Nicol responded to the ruling by highlighting systemic issues within the weight loss medication advertising landscape. "Today's ruling highlights the need for greater clarity across the weight loss medication market," Nicol stated. "When non-compliant advertising continues to appear so visibly on fast-moving digital channels, it creates confusion for consumers and gives the impression that some practices may be permissible when they are not."
Nicol further emphasized that while advertising rules may appear established theoretically, "the reality is that the current framework is still not providing enough clarity or consistent enough enforcement for a category that has evolved rapidly in recent years. That creates an uneven environment where responsible providers can be penalised while others are able to push at the boundaries."
The ASA has instructed Juniper to cease promoting prescription-only medicines to the public and ensure future advertising avoids creating undue urgency for consumers considering medicated weight-loss programmes. This ruling represents a significant enforcement action in the increasingly scrutinized digital health advertising sector, particularly concerning medications that require medical supervision and prescription.
